Evidence map›Paper›PMID 39996122›Full record

ArticleJHEP reports : innovation in hepatology2025

Liver transcriptome analysis reveals PSC-attributed gene set associated with fibrosis progression.

Alena Laschtowitz, Eric L Lindberg, Anna-Maria Liebhoff, Laura Anne Liebig, Christian Casar, Silja Steinmann, Adrien Guillot, Jun Xu, Dorothee Schwinge, Michael Trauner and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01672853 (A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01672853 phase2completednot on this map

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)

TypeinterventionalSponsorGilead SciencesRan2013 to 2016Enrolled235ConditionsPrimary Sclerosing Cholangitis (PSC)ArmsSimtuzumab, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Myeloid cells in chronic liver inflammation.Cellular & molecular immunology · 2025
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alena LaschtowitzDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eric L LindbergCardiovascular and Metabolic Sciences, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany.
Anna-Maria LiebhoffInstitute of Medical Systems Biology, Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Laura Anne LiebigDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian CasarDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Silja SteinmannDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Adrien GuillotDepartment of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jun XuDepartment of Biomarker Sciences, Gilead Sciences Inc., San Mateo, California, United States of America.
Dorothee SchwingeDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Michael TraunerEuropean Reference Network for Hepatological Diseases (ERN-RARE LIVER), Hamburg, Germany.
Ansgar Wilhelm LohseDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Stefan BonnInstitute of Medical Systems Biology, Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Norbert HübnerCardiovascular and Metabolic Sciences, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany.
Christoph SchrammDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Primary sclerosing cholangitis (PSC) is a chronic heterogenous cholangiopathy with unknown etiology where chronic inflammation of the bile ducts leads to multifocal biliary strictures and biliary fibrosis with consecutive cirrhosis development. We here aimed to identify a PSC-specific gene signature associated with biliary fibrosis development. Methods: We performed RNA-sequencing of 47 liver biopsies from people with PSC (n = 16), primary biliary cholangitis (PBC, n = 15), and metabolic dysfunction-associated steatotic liver disease (MASLD, n = 16) with different fibrosis stages to identify a PSC-specific gene signature associated with biliary fibrosis progression. For validation, we compared an external transcriptome data set of liver biopsies from people with PSC (n = 73) with different fibrosis stages (baseline samples from NCT01672853). Results: Differential gene expression analysis of the liver transcriptome from patients with PSC with advanced Conclusions: We reveal a PSC-attributed gene signature associated with biliary fibrosis development that may enable the identification of potential new biomarkers and therapeutic targets in PSC-related fibrogenesis. Impact and implications: Primary sclerosing cholangitis (PSC) is an inflammatory liver disease that is characterized by multifocal inflammation of bile ducts and subsequent biliary fibrosis. Herein, we identify a PSC-specific gene set of biliary fibrosis progression attributing to a uniquely complex milieu of different cell types, including innate and adaptive immune cells while neutrophils and macrophages showed an earlier involvement in fibrosis initiation in PSC in contrast to PBC and metabolic dysfunction-associated steatotic liver disease. Thus, our unbiased approach lays an important groundwork for further mechanistic studies for research into PSC-specific fibrosis.

Indexed as

Biliary fibrosisBulk RNA-sequencingLiver transcriptomePrimary sclerosing cholangitis

Identifiers

PMID39996122
PMCPMC11848773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.